Non-Current Assets
Available-for-Sale Securities (Non-Current)
Vertex Pharmaceuticals Available-for-Sale Securities (Non-Current) increased by 1.4% to $5.72B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 21.7%, from $4.70B to $5.72B. Over 2 years (FY 2022 to FY 2024), Available-for-Sale Securities (Non-Current) shows an upward trend with a 574.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ3 2015
Last reportedQ4 2025
Metric ID:
afs_securities_noncurrentHistorical Data
12 periods
| Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $112.20M | $1.08B | $1.36B | $1.70B | $2.50B | $4.38B | $4.39B | $4.70B | $5.11B | $5.16B | $5.65B | $5.72B |
| QoQ Change | — | +863.9% | +25.5% | +25.2% | +46.9% | +75.4% | +0.3% | +7.1% | +8.6% | +1.0% | +9.5% | +1.4% |
| YoY Change | — | — | — | — | >999% | +305.1% | +223.7% | +176.7% | +104.5% | +17.7% | +28.5% | +21.7% |
Range$112.20M – $5.72B
CAGR+317.8%
Avg YoY Growth+375.5%
Median YoY Growth+140.6%
Current Streak11+ quarters growth
Available-for-Sale Securities (Non-Current) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's available-for-sale securities (non-current)?
- Vertex Pharmaceuticals (VRTX) reported available-for-sale securities (non-current) of $5.72B in Q3 2025.
- How has Vertex Pharmaceuticals's available-for-sale securities (non-current) changed year-over-year?
- Vertex Pharmaceuticals's available-for-sale securities (non-current) increased by 21.7% year-over-year, from $4.70B to $5.72B.
- What is the long-term trend for Vertex Pharmaceuticals's available-for-sale securities (non-current)?
- Over 2 years (2022 to 2024), Vertex Pharmaceuticals's available-for-sale securities (non-current) has grown at a 574.7% compound annual growth rate (CAGR), from $112.20M to $5.11B.